Don't miss a thing by getting the latest from the Manchester Evening News sent direct to your inbox A drug commonly prescribed to treat inflammatory bowel disease (IBD) may be linked to reduced coronavirus antibody response, a new study suggests.
According to the study, people who take infliximab may be more at risk of reinfection because the drug blunts the immune system to Covid-19 infection.
Now, researchers say careful monitoring of patients with IBD treated with infliximab, who have been vaccinated against the virus, will be needed to ensure they mount a strong enough antibody response to ward off the infection.
The Clarity study, which has been published in the Gut journal, recruited 6,935 patients with Crohn’s disease and ulcerative